SMARCD3

Across TCGA pan-cancer cohorts, SMARCD3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SMARCD3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SMARCD3 RNA is repressed in tumor relative to normal tissue. In most cancer types SMARCD3 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

KIRC, LUSC, and BLCA are the cancer types where SMARCD3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMARCD3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.909	<.001	11	view →
LUSC	Female	II,III,IV	−1.575	<.001	9	view →
BLCA	Male	All	−1.544	.003	8	view →
HNSC	Male	All	−1.170	<.001	8	view →
LUAD	Male	II,III,IV	−0.986	<.001	8	view →
THCA	Female	II,III,IV	+0.815	<.001	8	view →
LIHC	Female	All	+1.135	<.001	7	view →
BRCA	Female	All	−0.665	<.001	6	view →
STAD	All	All	−0.779	.006	5	view →
UCEC	All	All	−1.300	<.001	4	view →
KIRP	All	All	+0.876	<.001	4	view →
COAD	All	All	−0.376	.012	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SMARCD3–KIRC

Open the KIRC breakdown →